Open AccessClearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐X L –BAX interaction
Author(s) -
Saleh Tareq,
Carpenter Valerie J.,
TyutyunykMassey Liliya,
Murray Graeme,
Leverson Joel D.,
Souers Andrew J.,
Alotaibi Moureq R.,
Faber Anthony C.,
Reed Jason,
Harada Hisashi,
Gewirtz David A.
Publication year - 2020
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12761
Subject(s) - etoposide , cancer research , senescence , doxorubicin , cancer , medicine , in vivo , chemotherapy , biology , microbiology and biotechnology
Senescent tumor cells can be selectively eliminated by the BH3 mimetic, ABT‐263 (navitoclax), via senolysis. We show that ABT‐263 inhibits the interaction between anti‐apoptotic BCL‐2 family member, BCL‐X L , and pro‐apoptotic effector, BAX. This results in senescent tumor cell death in vitro and reduced tumor volume in vivo . This work highlights the utilization of senolytic agents to enhance efficacy of anticancer therapy.